- Home
- MSTR vs BMY Comparison
MSTR vs BMY Comparison
Compare MSTR & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSTR
- BMY
- Stock Information
- Founded
- MSTR 1989
- BMY 1887
- Country
- MSTR United States
- BMY United States
- Employees
- MSTR N/A
- BMY N/A
- Industry
- MSTR Computer Software: Prepackaged Software
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- MSTR Technology
- BMY Health Care
- Exchange
- MSTR Nasdaq
- BMY Nasdaq
- Market Cap
- MSTR 106.8B
- BMY 99.7B
- IPO Year
- MSTR 1998
- BMY N/A
- Fundamental
- Price
- MSTR $403.00
- BMY $46.60
- Analyst Decision
- MSTR Strong Buy
- BMY Hold
- Analyst Count
- MSTR 11
- BMY 15
- Target Price
- MSTR $469.27
- BMY $58.93
- AVG Volume (30 Days)
- MSTR 12.0M
- BMY 11.7M
- Earning Date
- MSTR 07-31-2025
- BMY 07-31-2025
- Dividend Yield
- MSTR N/A
- BMY 5.29%
- EPS Growth
- MSTR N/A
- BMY N/A
- EPS
- MSTR N/A
- BMY 2.67
- Revenue
- MSTR $459,276,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- MSTR $1.77
- BMY N/A
- Revenue Next Year
- MSTR $3.43
- BMY N/A
- P/E Ratio
- MSTR N/A
- BMY $17.55
- Revenue Growth
- MSTR N/A
- BMY 4.62
- 52 Week Low
- MSTR $102.40
- BMY $44.00
- 52 Week High
- MSTR $543.00
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- MSTR 44.97
- BMY 45.53
- Support Level
- MSTR $390.41
- BMY $47.29
- Resistance Level
- MSTR $417.01
- BMY $49.28
- Average True Range (ATR)
- MSTR 14.88
- BMY 1.12
- MACD
- MSTR -5.57
- BMY 0.05
- Stochastic Oscillator
- MSTR 10.34
- BMY 22.26
About MSTR MicroStrategy Incorporated
Strategy is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provide industry AI-powered enterprise analytics software.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.